Ezutromid

Research use only, not for human use.

The first orally bioavailable small molecule utrophin upregulator.

The first orally bioavailable small molecule utrophin upregulator; demonstrates significant disease modifying effects in DMD models; reduces a number of the pathological effects of dystrophin deficiency, results in reduced pathology, better muscle physiology leading to an increase in overall strength, and an ability to resist fatigue after forced exercise.(In Vitro):Ezutromid induces increased levels of utrophin RNA in human muscle cells. Treatment of human DMD cells with Ezutromid lead to a 2-fold increase in utrophin protein levels at an optimal concentration of 0.3 uM after 3 days of treatment. Ezutromid was safe and well tolerated with plasma concentrations achieved suf cient to cause a 50% increase in concentrations of utrophin in cells. Ezutromid led to a 30% increase in Utrn mRNA level and resulted in a 2.0-fold increase in UTRN protein level.(In Vivo):Note: You can dissolve the products in phosphate buffered saline (PBS), 0.1% Tween-20, 5% DMSO).

Ezutromid induces increased levels of utrophin RNA in human muscle cells. Treatment of human DMD cells with Ezutromid lead to a 2-fold increase in utrophin protein levels at an optimal concentration of 0.3 uM after 3 days of treatment. Ezutromid was safe and well tolerated with plasma concentrations achieved suf cient to cause a 50% increase in concentrations of utrophin in cells.Ezutromid led to a 30% increase in Utrn mRNA level and resulted in a 2.0-fold increase in UTRN protein level.

Note: You can dissolve the products in phosphate buffered saline (PBS), 0.1% Tween-20, 5% DMSO) .

SMT-C1100 | VOX-C1100 | BMN-195

Others

Other Targets

Others

Other Indications

Other Disease

945531-77-1

337.3923

C19H15NO3S

>98% (HPLC)

DMSO: 10 mg/mL

O=S(C1=CC=C(OC(C2=CC=C3C=CC=CC3=C2)=N4)C4=C1)(CC)=O

Benzoxazole, 5-(ethylsulfonyl)-2-(2-naphthalenyl)-

(-20℃)

With Ice Pack

≥ 2 years